The global blood glucose monitor market is set to expand from USD 16.5 billion in 2025 to USD 25.4 billion by 2030, growing ...

Morgan Stanley analyst Patrick Wood upgraded the stock to Overweight from Equal Weight on Tuesday, citing a favorable ...

Investors encouraged to join DexCom class action lawsuit. Allegations include unapproved design changes to G6/G7 glucose ...

In late November Abbott—one of Dexcom’s main competitors— recalled some of its CGMs due to inaccurate low glucose readings.

The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...

A Dexcom (NSDQ:DXCM) communication on its website states that it will soon cease manufacturing for its G6 continuous glucose ...

Continuous glucose monitoring may have a role in identifying and preventing diabetes among healthy adults, but more studies ...

DexCom has been in for a rough ride this year. The medical technology company is grappling with concerns over its slowing growth and allegations of faulty blood glucose monitors.

SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over ...

DexCom, Inc. (NASDAQ:DXCM) is one of the stocks on Jim Cramer’s radar recently. A caller asked if they should buy, sell, or hold the stock during the lightning round. In response, Cramer said: “You ...

Dexcom (Nasdaq:DXCM) today announced the launch of Dexcom Academy, a new, personalized learning platform for healthcare ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...